Rapport Therapeutics, Inc. Common Stock (RAPP) Stock Forecast & Price Target
Rapport Therapeutics, Inc. Common Stock · NASDAQ
$42.15+1.47 (+3.61%)
15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 6 firms covering Rapport Therapeutics, Inc. Common Stock, 6 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets are tightly clustered, $52.00 to $65.00, so the covering firms are broadly aligned. The average target of $57.67 sits 37% above the current $42.15. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-1.01 next quarter toward $-4.40 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS6 ratings
Moderate Buy
Strong Buy00%
Buy6100%
Hold00%
Sell00%
Strong Sell00%
Based on 6 analysts giving stock ratings to Rapport Therapeutics, Inc. Common Stock.
As of Jul, 6 of 6 firms rate RAPP a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
RAPP EPS & revenue forecast
EPS · NEXT QUARTER
$-1.01
Range $-1.07 – $-0.82 · 7 analysts · +42% YoY
Next period, 7 analysts expect Rapport Therapeutics, Inc. Common Stock to earn $-1.01 a share (range $-1.07 – $-0.82), versus $-0.71 a year earlier. Full-year consensus is $-3.46, growing to $-4.40 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 7 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $20.0M, rising to $0 next year.
Top analysts covering Rapport Therapeutics, Inc. Common Stock
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on RAPP.
#1
Jason Butler
JMP Securities · Rank #22
Buy
$80.00+89.8% to target
Overall win rate
57%
+ Follow
#2
Douglas Tsao
HC Wainwright & Co. · Rank #212
Buy
$40.00-5.1% to target
Overall win rate
35%
+ Follow
#3
KY
Kambiz Yazdi
BTIG
Buy
$65.00+54.2% to target
Coverage
—
+ Follow
#4
Marc Goodman
Leerink Partners
Buy
$52.00+23.4% to target
Coverage
—
+ Follow
#5
DB
Danielle Brill
Truist Securities
Buy
$56.00+32.9% to target
Coverage
—
+ Follow
RAPP stock forecast FAQ
What is RAPP's average 12-month price target?+
The 3 analysts with a live target average $57.67 for Rapport Therapeutics, Inc. Common Stock over the next 12 months, ranging from a $65.00 high to a $52.00 low.
Is RAPP stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 6 analyst ratings, 6 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for RAPP?+
The Street-high target is $65.00 (BTIG), and the Street-low is $52.00 (Leerink Partners). The average of all 3 active targets is $57.67.
How many Wall Street analysts cover RAPP?+
6 analysts have an active rating on Rapport Therapeutics, Inc. Common Stock, and 3 firms carry a live 12-month price target.
Who is the most accurate analyst covering RAPP?+
Among analysts who currently cover RAPP, Jason Butler of JMP Securities has the strongest overall Quantellect track record (Rank #22). Their current call is Buy with a $80.00 target.
What is Rapport Therapeutics, Inc. Common Stock's projected EPS for next quarter?+
The consensus estimate is $-1.01 per share (range $-1.07 – $-0.82) across 7 analysts. Full-year EPS is projected at $-3.46, rising to $-4.40 the following year.
How much revenue is Rapport Therapeutics, Inc. Common Stock expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $20.0M, growing to $0 next year.
Have analysts been upgrading or downgrading RAPP lately?+
As of Jul, 6 of 6 firms rate RAPP a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their RAPP calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
